×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NVO – novo nordisk a/s (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NVO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/28
10:25 am
nvo
Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product' [MSNBC.com]
Low
Report
Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product' [MSNBC.com]
3/28
06:50 am
nvo
Weekly Recap: 15 Health Press Releases You Need to See [Yahoo! Finance]
Low
Report
Weekly Recap: 15 Health Press Releases You Need to See [Yahoo! Finance]
3/28
06:29 am
nvo
Novo Nordisk says compounded drugs are hurting Wegovy sales [CNBC]
Low
Report
Novo Nordisk says compounded drugs are hurting Wegovy sales [CNBC]
3/27
05:01 pm
nvo
Pharma industry races to stockpile medicines before potential tariffs [USA TODAY]
Low
Report
Pharma industry races to stockpile medicines before potential tariffs [USA TODAY]
3/27
02:25 pm
nvo
Novo Nordisk says copycat compounders are hurting Wegovy sales, may take legal action [MSNBC.com]
Low
Report
Novo Nordisk says copycat compounders are hurting Wegovy sales, may take legal action [MSNBC.com]
3/27
10:10 am
nvo
1 Growth Stock Down 40% to Buy and Hold Forever [Yahoo! Finance]
Low
Report
1 Growth Stock Down 40% to Buy and Hold Forever [Yahoo! Finance]
3/27
02:18 am
nvo
You can buy now, pay later for weight-loss drugs: Here's what you need to know [Yahoo! Finance]
Low
Report
You can buy now, pay later for weight-loss drugs: Here's what you need to know [Yahoo! Finance]
3/26
08:43 am
nvo
Intron Health's Naresh Chouhan explains why he's downgrading Novo Nordisk from buy to sell [CNBC]
Low
Report
Intron Health's Naresh Chouhan explains why he's downgrading Novo Nordisk from buy to sell [CNBC]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/10
07:58 am
nvo
Form 6-K NOVO NORDISK A S For: Mar 10
Medium
Report
Form 6-K NOVO NORDISK A S For: Mar 10
2/27
10:59 am
nvo
Form 6-K NOVO NORDISK A S For: Feb 27
Low
Report
Form 6-K NOVO NORDISK A S For: Feb 27
2/10
10:09 am
nvo
Form IRANNOTICE NOVO NORDISK A S
Low
Report
Form IRANNOTICE NOVO NORDISK A S
2/7
08:27 am
nvo
Form 6-K NOVO NORDISK A S For: Feb 07
Low
Report
Form 6-K NOVO NORDISK A S For: Feb 07
2/6
07:37 am
nvo
Form 6-K NOVO NORDISK A S For: Feb 06
Low
Report
Form 6-K NOVO NORDISK A S For: Feb 06
2/5
07:18 am
nvo
Form 6-K NOVO NORDISK A S For: Dec 31
Low
Report
Form 6-K NOVO NORDISK A S For: Dec 31
2/5
07:12 am
nvo
Form 6-K NOVO NORDISK A S For: Dec 31
Low
Report
Form 6-K NOVO NORDISK A S For: Dec 31
2/5
07:07 am
nvo
Form 20-F NOVO NORDISK A S For: Dec 31
Low
Report
Form 20-F NOVO NORDISK A S For: Dec 31
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/17
Form 6-K NOVO NORDISK A S For: Mar 16
6.0%
3/16 Novo Nordisk A/S (NYSE: NVO) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. 4.7%
2/5 Q4/2019 12/31/2019 EPS 3.700 ZacksConsensus 0.550 ActVsEst 3.150 - Beat 4.6%
6/8 Novo's oral semaglutide successful in two late-stage T2D studies [Seeking Alpha] 3.8%
11/8 Novo Nordisk: Actual Numbers Not As Good As Headlines But Still Quite Solid [Seeking Alpha] 3.2%
3/27 Form 6-K NOVO NORDISK A S For: Mar 26 3.2%
8/12 Q2/2019 6/30/2019 EPS 4.030 ZacksConsensus 0.610 ActVsEst 3.420 - Beat 3.0%
9/17 With a backup to the backup, insulin makers say they're primed for Brexit [Reuters (UK)] 3.0%
11/1 Form 6-K NOVO NORDISK A S For: Nov 01 2.7%
8/8 Europe stocks climb in early action, led by pharmas [MarketWatch] 2.4%
3/16 Novo Nordisk A/S (NYSE: NVO) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. 4.7%
2/5 Q4/2019 12/31/2019 EPS 3.700 ZacksConsensus 0.550 ActVsEst 3.150 - Beat 4.6%
6/8 Novo's oral semaglutide successful in two late-stage T2D studies [Seeking Alpha] 3.8%
11/8 Novo Nordisk: Actual Numbers Not As Good As Headlines But Still Quite Solid [Seeking Alpha] 3.2%
3/27 Form 6-K NOVO NORDISK A S For: Mar 26 3.2%
8/12 Q2/2019 6/30/2019 EPS 4.030 ZacksConsensus 0.610 ActVsEst 3.420 - Beat 3.0%
9/17 With a backup to the backup, insulin makers say they're primed for Brexit [Reuters (UK)] 3.0%
11/1 Form 6-K NOVO NORDISK A S For: Nov 01 2.7%
8/8 Europe stocks climb in early action, led by pharmas [MarketWatch] 2.4%
TOP News Decliners
9/9
Form 6-K NOVO NORDISK A S For: Sep 09
-3.6%
11/20 Form 6-K NOVO NORDISK A S For: Nov 20 -2.8%
12/18 Form 6-K NOVO NORDISK A S For: Dec 16 -2.5%
3/9 Form 6-K NOVO NORDISK A S For: Mar 09 -2.4%
4/7 Team Novo Nordisk and Beyond Type 1 Announce New Partnership -2.4%
1/3 Novo Nordisk: A Rare Case of Pharma With Balanced Risk and Reward [Yahoo! Finance News] -2.2%
4/28 Form 6-K NOVO NORDISK A S For: Apr 27 -2.1%
9/10 Novo Nordisk A/S (NYSE: NVO) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -2.1%
3/23 Form 6-K NOVO NORDISK A S For: Mar 23 -1.8%
10/1 Form 6-K NOVO NORDISK A S For: Sep 30 -1.6%
11/20 Form 6-K NOVO NORDISK A S For: Nov 20 -2.8%
12/18 Form 6-K NOVO NORDISK A S For: Dec 16 -2.5%
3/9 Form 6-K NOVO NORDISK A S For: Mar 09 -2.4%
4/7 Team Novo Nordisk and Beyond Type 1 Announce New Partnership -2.4%
1/3 Novo Nordisk: A Rare Case of Pharma With Balanced Risk and Reward [Yahoo! Finance News] -2.2%
4/28 Form 6-K NOVO NORDISK A S For: Apr 27 -2.1%
9/10 Novo Nordisk A/S (NYSE: NVO) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -2.1%
3/23 Form 6-K NOVO NORDISK A S For: Mar 23 -1.8%
10/1 Form 6-K NOVO NORDISK A S For: Sep 30 -1.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: